Clinical operations

What Insmed’s TPIP extension study brings to Phase 3 in PAH

Explore Novo Nordisk’s Q3 2026 GLP-1 growth, CagriSema trial results, and implications for clinical operations, patient access and evidence quality.

By Lampgen Clinical Research

1 min read · estimated

Sources
12 months91 participants
Open-label extension reported by Insmed

What the source reported

Insmed reported sustained improvements in six-minute walk distance and NT-proBNP at 12 months in an open-label extension of investigational once-daily inhaled TPIP for pulmonary arterial hypertension. The extension followed participants from earlier studies without a concurrent placebo group.

What this means for trial teams

The extension adds longer-term observations on tolerability and functional outcomes. The randomized Phase 3 PALM-PAH study evaluates efficacy against placebo. Consistent walk-test administration, inhaler training, and tracking missed visits will help sites collect interpretable data across centers.

Sources

  1. Insmed 12-month data release
  2. Original Lampgen LinkedIn post

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?